To include your compound in the COVID-19 Resource Center, submit it here.

BMS expanding I-O portfolio through IFM acquisition

Bristol-Myers Squibb Co. (NYSE:BMY) will acquire IFM Therapeutics Inc. (Boston, Mass.), gaining two preclinical programs focused on stimulating the innate immune system to treat cancer.

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE